Zacks Research Comments on Editas Medicine, Inc.’s Q3 2025 Earnings (NASDAQ:EDIT)

Editas Medicine, Inc. (NASDAQ:EDIT) – Equities research analysts at Zacks Research reduced their Q3 2025 earnings estimates for shares of Editas Medicine in a research report issued on Tuesday, June 25th. Zacks Research analyst A. Chakraborty now anticipates that the company will post earnings of ($0.74) per share for the quarter, down from their previous forecast of ($0.73). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.70) per share. Zacks Research also issued estimates for Editas Medicine’s Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.87) EPS, Q1 2026 earnings at ($0.71) EPS and FY2026 earnings at ($2.75) EPS.

A number of other analysts have also recently issued reports on the stock. Morgan Stanley upgraded shares of Editas Medicine from an “underweight” rating to an “equal weight” rating and set a $7.00 target price for the company in a research note on Thursday, May 9th. Evercore ISI decreased their price objective on shares of Editas Medicine from $15.00 to $7.00 and set an “in-line” rating for the company in a report on Thursday, May 30th. StockNews.com lowered Editas Medicine from a “hold” rating to a “sell” rating in a report on Thursday, May 9th. Oppenheimer reaffirmed a “market perform” rating and issued a $12.00 price target on shares of Editas Medicine in a research report on Tuesday, June 18th. Finally, Barclays lowered their price objective on Editas Medicine from $11.00 to $9.00 and set an “equal weight” rating on the stock in a report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Editas Medicine has a consensus rating of “Hold” and a consensus price target of $12.90.

Editas Medicine Price Performance

Shares of NASDAQ EDIT opened at $4.74 on Friday. The business has a 50 day simple moving average of $5.41 and a 200 day simple moving average of $7.36. Editas Medicine has a 52 week low of $4.68 and a 52 week high of $11.69.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Wednesday, May 8th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.13). Editas Medicine had a negative net margin of 239.36% and a negative return on equity of 47.34%. The firm had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $11.14 million. During the same quarter last year, the firm earned ($0.71) EPS. The business’s revenue for the quarter was down 88.9% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EDIT. Kennedy Capital Management LLC bought a new stake in shares of Editas Medicine in the first quarter valued at about $988,000. Bayesian Capital Management LP bought a new stake in shares of Editas Medicine in the 1st quarter worth approximately $181,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Editas Medicine by 16.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,704 shares of the company’s stock worth $369,000 after purchasing an additional 7,174 shares in the last quarter. EntryPoint Capital LLC bought a new stake in shares of Editas Medicine during the first quarter valued at approximately $72,000. Finally, Shell Asset Management Co. raised its stake in shares of Editas Medicine by 33.5% in the first quarter. Shell Asset Management Co. now owns 87,967 shares of the company’s stock valued at $653,000 after purchasing an additional 22,083 shares in the last quarter. Institutional investors own 71.90% of the company’s stock.

Insider Buying and Selling

In other Editas Medicine news, Director Jessica Hopfield bought 45,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average price of $5.64 per share, for a total transaction of $253,800.00. Following the purchase, the director now directly owns 67,700 shares in the company, valued at $381,828. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Editas Medicine news, Director Jessica Hopfield purchased 45,000 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was bought at an average cost of $5.64 per share, for a total transaction of $253,800.00. Following the completion of the acquisition, the director now directly owns 67,700 shares in the company, valued at $381,828. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Gilmore Neil O’neill sold 12,191 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $5.50, for a total value of $67,050.50. Following the completion of the sale, the chief executive officer now directly owns 315,279 shares of the company’s stock, valued at $1,734,034.50. The disclosure for this sale can be found here. 1.90% of the stock is owned by insiders.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.